The Motley Fool

2 cheap stocks I think Warren Buffett would love

close-up photo of investor Warren Buffett
Image source: The Motley Fool

Warren Buffett is one of the most successful, and by extension most famous, value-loving investors in the business. Picking low-cost stocks with his Berkshire Hathaway firm and watching them balloon in value has made the ‘Sage of Omaha’ worth an estimated $100.4bn today.

But Buffett’s investing strategy is about much more than just identifying undervalued stocks. Here are two cheap UK shares I think would whet the billionaire investor’s appetite for other reasons.

One Killer Stock For The Cybersecurity Surge

Cybersecurity is surging, with experts predicting that the cybersecurity market will reach US$366 billion by 2028more than double what it is today!

And with that kind of growth, this North American company stands to be the biggest winner.

Because their patented “self-repairing” technology is changing the cybersecurity landscape as we know it…

We think it has the potential to become the next famous tech success story. In fact, we think it could become as big… or even BIGGER than Shopify.

Click here to see how you can uncover the name of this North American stock that’s taking over Silicon Valley, one device at a time…

The FTSE 100 pharma giant

Buying companies which have clear and effective ‘economic moats’ is a cornerstone of Buffett’s money-making strategy. This is the name given to any long-term advantage a business has over the competition. They can include anything from market-leading products and a lower cost base versus rival operators, to creating high switching costs for customers looking to take their custom elsewhere.

GlaxoSmithKline (LSE: GSK) has one of the most formidable economic moats out there, namely significant patent protection. This stops rival drugs manufacturers moving in and copying its expensively-assembled portfolio of world-class treatments. According to DrugPatentWatch, the FTSE 100 company has 1,048 product patents in effect spanning 59 countries.

Pharmaceuticals development is a notoriously difficult business. And GlaxoSmithKline’s great track record of producing market-leading patented products is no guarantee of future success. But I’d argue that this UK share’s undemanding forward price-to-earnings (P/E) ratio of around 13 times still offers terrific value. Especially considering its strong position in many fast-growing therapy areas like oncology, vaccines and respiratory disorders, and the enormous financial clout it has to plough into R&D.

I think Buffett, who already owns Merck and Bristol Myers Squibb, would love this UK share.

Another stock Warren Buffett might adore

The popularity of Britvic’s (LSE: BVIC) brands seems to be timeless. The likes of Pepsi, Robinsons, Lipton and R Whites have been keeping consumers refreshed for many decades (some even have their roots in the 1800s). And their popularity is a strong as ever.

Buffett loves firms with robust brand power, as shown by Berkshire Hathaway’s holdings in Apple, Kraft Heinz and Coca-Cola. This economic moat helps demand for their products grow stronger than the broader market when consumer spending comes under pressure. It also allows companies like Britvic to raise prices without having to worry too much about how this will affect sales volumes.

I think Britvic’s a top buy despite the threat posed by a growing carbon dioxide shortage, a critical component in the company’s fizzy drinks. European fertilizer plants are shutting down operations in response to soaring energy prices, including two major facilities here in the UK. This could naturally damage beverages production and jack up costs considerably.

City analysts currently think Britvic’s earnings will jump 24% in the upcoming financial year (to September 2022). This leaves it trading on a bargain-basement forward price-to-earnings growth (PEG) ratio of 0.7. In my opinion, this provides the sort of bang for your buck that value investors like Warren Buffett adore.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended Apple and Bristol Myers Squibb. The Motley Fool UK has recommended Britvic and GlaxoSmithKline and has recommended the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.